|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||17.00 - 17.60|
|52-week range||7.30 - 18.75|
|PE ratio (TTM)||N/A|
|Earnings date||8 May 2018 - 14 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||32.67|
On a per-share basis, the New York-based company said it had a loss of 93 cents. For the year, the company reported that its loss widened to $67.8 million, or $2.94 per share. Revenue was reported as $898,000. ...
NEW YORK, Jan. 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the closing of a previously announced underwritten public offering of 4,255,000 shares of its common stock, which included the exercise in full of the option to purchase 555,000 additional shares, at a price of $14.00 per share. ...
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
The New York-based company said it had a loss of 68 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...